Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Published Time:
2021-03-12 17:39
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
IBD encompasses chronic, non-specific inflammatory conditions of the gut, primarily ulcerative colitis (UC) and Crohn's disease (CD). Clinical manifestations include diarrhea, abdominal pain, and even bloody stools. UC can occur at any age, with peaks between 15-30 and 50-70 years old. It primarily affects the rectum and sigmoid colon, exhibiting diffuse distribution. CD can also occur at any age but is most common in adolescence. Lesions can affect the entire gastrointestinal tract from mouth to anus, characterized by segmental and skip lesions, most frequently involving the terminal ileum, colon, or both the small and large intestine. Both UC and CD are chronic inflammatory diseases currently without a cure, requiring lifelong medication management. Often termed "incurable intestinal disorders," they carry high relapse rates of 70–90%. The incidence of IBD in China is steadily increasing, establishing it as a common and challenging condition within the digestive system. It represents a key focus and significant challenge in both basic research and clinical diagnosis/treatment of digestive diseases.
Janus kinases (JAKs) comprise a family of tyrosine kinases, consisting of four members: JAK1, JAK2, JAK3, and TYK2. JAKs play crucial roles in signal transduction for numerous cytokines. Together with their downstream effectors, Signal Transducers and Activators of Transcription (STATs), they mediate cytokine receptor regulation of nuclear gene transcription and expression. Dysfunction of the JAK-STAT signaling pathway is closely associated with the pathogenesis of hematological diseases such as polycythemia vera, thrombocythemia, leukemia, and myelofibrosis, as well as autoimmune disorders including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), IBD, and atopic dermatitis. Consequently, the JAK kinase family has emerged as a critical therapeutic target for these conditions.
About VC005
VC005 is a novel, potent, gut-restricted selective JAK1 inhibitor independently developed by Jiangsu Vcare. It features controllable systemic exposure coupled with high intestinal exposure. Preclinical studies have demonstrated that VC005 exhibits a low effective dose, high tolerated dose, and minimal side effects in animal models, offering dual advantages of safety and efficacy. It holds promise as a potential globally leading gut-selective anti-inflammatory drug.
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn